Kihlbom has recently argued that a system of seeking negatively informed consent might be preferable in some cases to the ubiquitous informed consent model. Although this theory is perhaps not powerful enough to supplant informed consent in most settings, it lends strength to Evans’ and Hungin’s proposal that it can be ethical to prescribe placebos rather than “active” drugs. This paper presents an argument for using negatively informed consent for the specific purpose of authorising the use of placebos in clinical contexts.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding: This research was internally funded.
Competing interests: None.
Read the full text or download the PDF:
Other content recommended for you
- The thinking doctor’s guide to placebos
- Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
- Replication crisis and placebo studies: rebooting the bioethical debate
- Physician perspectives on placebo ethics
- Randomised placebo-controlled trials of surgery: ethical analysis and guidelines
- The ethics of placebo treatments in clinical practice: a reply to Glackin
- Placebo effects and the molecular biological components involved
- Patients’ attitudes about the use of placebo treatments: telephone survey
- The moral case for the clinical placebo
- The ethics of the placebo in clinical practice revisited